17,261 trials
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Objective Response Rate (ORR) Per mRECIST (Modified RECIST) — 1 Participants
Binge-Eating Disorder
Primary: Change From Baseline to Week 12 in the Number of Binge Eating (BE) Days Per Week — -2.93; -2.93 BE days per week — p=0.9992
Hip Fractures · Intertrochanteric Fractures
Primary: Number of Subjects Transfused at Least 1 Unit of Packed Red Blood Cells — 17; 19 Participants
Rheumatoid Arthritis
Primary: The Primary Outcome Measure is the Determination of the Safety and Tolerability of ATI-450 Plus Methotrexate in Patients With Moderate to Severe Rheumatoid Arthritis…
Irritable Bowel Syndrome With Diarrhea
Primary: Change in Stool Form — -0.26; -0.45; -0.49 score on a scale
Urinary Bladder Neoplasm · Neoplasm Metastasis
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have…
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Non-infectious Anterior Uveitis
Primary: Anterior Chamber Cell Grade at Week 8 — -0.7; -0.9; -0.5 units on a scale
Atherosclerotic Cardiovascular Disease · Symptomatic Atherosclerosis · Type2 Diabetes
Primary: Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm) — -47.48 Percentage Change
Hematologic Neoplasms
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation — 3; 9; 5; 19 Participants
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Part 2: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 14 - Study Eye — 26.3; 26.1; 27.1; 24.8 millimeters of mercury (mm Hg) — p=<0.001
Lung Neoplasms · Lung Cancer
Primary: Sensitivity or True Positive Rate (TPR) — 0.854 proportion of lesions
Ovarian Cancer
Primary: Time to Recurrence (TTR) — 18.2; 12.4 months
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen — 17.8 percentage of participants
Metastatic Castration-resistant Prostate Cancer
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort 1, Cohort 2, Cohort 4 and Cohorts 1 and 2 Combined) — 6.0; 3.0; 12.3…